Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sinaptica Therapeutics, Inc.

Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
From Sinaptica Therapeutics, Inc.
Via Business Wire
Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025
From Sinaptica Therapeutics, Inc.
Via Business Wire
Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints
From Sinaptica Therapeutics, Inc.
Via Business Wire
Sinaptica Therapeutics to Present Results of 52-week Phase 2 Study of Precision Neuromodulation for Alzheimer’s Diseases in Oral Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Sinaptica Therapeutics, Inc.
Via Business Wire
Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity in Key Brain Network in Alzheimer’s Patients
From Sinaptica Therapeutics, Inc.
Via Business Wire
Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot
From Sinaptica Therapeutics, Inc.
Via Business Wire
Sinaptica Completes Scientific Advisory Board with Final Expert Appointment as Company Advances to Pivotal Trial in Alzheimer’s
From Sinaptica Therapeutics, Inc.
Via Business Wire
Sinaptica Appoints Ken Mariash as Chief Executive Officer
From Sinaptica Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.